Literature DB >> 20854073

Primary central nervous system lymphoma: a clinicopathological study of 75 cases.

Matthias Preusser1, Adelheid Woehrer, Oskar Koperek, Andrea Rottenfusser, Karin Dieckmann, Brigitte Gatterbauer, Karl Roessler, Irene Slavc, Ulrich Jaeger, Berthold Streubel, Johannes A Hainfellner, Andreas Chott.   

Abstract

AIMS: Pathological and clinical data in a large series of immunocompetent patients with primary lymphoma of the central nervous system (PCNSL) were analysed.
METHODS: We immunostained tumour specimens of 75 patients for CD3, CD4, CD5, CD8, CD10, CD20, CD30, CD79a, Bcl-2, Bcl-6, CD138, MUM1, TDT, PAX5, FOXP1 and Ki-67 and performed in situ hybridisation for Epstein-Barr virus (EBV) RNA. Eleven cases were investigated for rearrangements of BCL6, immunoglobulin heavy chain (IGH) and FOXP1 genes using fluorescent in situ hybridisation (FISH).
RESULTS: Histologically, most cases were classified as diffuse large B-cell lymphoma (80.2%) predominantly of centroblastic type. Immunophenotypic profiling revealed that 96% and 4% of cases corresponded to non-germinal centre and germinal centre type, respectively. FISH analysis showed t(3;14)/IGH-BCL6 in 2/11 cases and trisomy 3 in 2/11 cases. FOXP1 rearrangements were not found. At survival analysis, Karnofsky index >80 and presence of Bcl-6 expression showed independent significant association with favourable patient outcome.
CONCLUSIONS: PCNSL represents a histologically and immunophenotypically very homogeneous lymphoma type, probably derived from germinal centre exit B cells. The frequent overexpression of FOXP1 appears not to be related to FOXP1 gene rearrangement. Survival analyses disclosed Bcl-6 expression and high Karnofsky performance score as independent prognostic parameters associated with favourable outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854073     DOI: 10.3109/00313025.2010.508786

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  13 in total

1.  Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.

Authors:  Stephan Kreher; Korinna Jöhrens; Felicitas Strehlow; Peter Martus; Kathrin Borowiec; Josefine Radke; Frank Heppner; Patrick Roth; Eckhard Thiel; Torsten Pietsch; Michael Weller; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2015-03-26       Impact factor: 12.300

2.  Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla.

Authors:  Shanshan Jiang; Hao Yu; Xianlong Wang; Shilong Lu; Yufa Li; Lyujin Feng; Yi Zhang; Hye-Young Heo; Dong-Hoon Lee; Jinyuan Zhou; Zhibo Wen
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

Review 3.  Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?

Authors:  K Grace Ho; Christian Grommes
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

4.  Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.

Authors:  Danhui Li; Shengjie Li; Zuguang Xia; Jiazhen Cao; Jinsen Zhang; Bobin Chen; Xin Zhang; Wei Zhu; Jianchen Fang; Qiang Liu; Wei Hua
Journal:  EPMA J       Date:  2022-07-15       Impact factor: 8.836

5.  Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases.

Authors:  Jing Liu; Yaming Wang; Yuantao Liu; Zhe Liu; Qu Cui; Nan Ji; Shengjun Sun; Bingxu Wang; Yajie Wang; Xuefei Sun; Yuanbo Liu
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

Review 6.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

7.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

8.  Primary pediatric mid-brain lymphoma: Report of a rare pediatric tumor in a rare location.

Authors:  Rony Benson; Supriya Mallick; Suvendu Purkait; Vaishali Suri; K P Haresh; Subhash Gupta; Dayanand Sharma; Pramod Kumar Julka; Goura Kishore Rath
Journal:  World J Clin Cases       Date:  2016-12-16       Impact factor: 1.337

9.  Expression of Tim-1 in primary CNS lymphoma.

Authors:  Wataru Kishimoto; Momoko Nishikori; Hiroshi Arima; Hiroaki Miyoshi; Yuya Sasaki; Toshio Kitawaki; Kotaro Shirakawa; Takeharu Kato; Yoshitaka Imaizumi; Takayuki Ishikawa; Hitoshi Ohno; Hironori Haga; Koichi Ohshima; Akifumi Takaori-Kondo
Journal:  Cancer Med       Date:  2016-10-05       Impact factor: 4.452

10.  Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.

Authors:  Ni Fan; Lu Zhang; Xiaoping Xu; Bobin Chen; Chen Zhu; Pei Li; Zi Chen; Tianling Ding; Yan Ma; Yan Yuan; Zhiguang Lin
Journal:  Oncotarget       Date:  2017-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.